DK1933843T3 - Anvendelse af østradiolvalerat eller østradiol kombineret med dienogest til oral terapi af dysfunktionel livmoderblødning i forening med oral prævention - Google Patents

Anvendelse af østradiolvalerat eller østradiol kombineret med dienogest til oral terapi af dysfunktionel livmoderblødning i forening med oral prævention

Info

Publication number
DK1933843T3
DK1933843T3 DK06806225.6T DK06806225T DK1933843T3 DK 1933843 T3 DK1933843 T3 DK 1933843T3 DK 06806225 T DK06806225 T DK 06806225T DK 1933843 T3 DK1933843 T3 DK 1933843T3
Authority
DK
Denmark
Prior art keywords
estradiol
oral
dienogest
association
uterine bleeding
Prior art date
Application number
DK06806225.6T
Other languages
English (en)
Inventor
Susan Zeun
Pol Boudes
Angelo Secci
Holger Zimmermann
Jan Endrikat
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35811580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1933843(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of DK1933843T3 publication Critical patent/DK1933843T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DK06806225.6T 2005-10-13 2006-10-12 Anvendelse af østradiolvalerat eller østradiol kombineret med dienogest til oral terapi af dysfunktionel livmoderblødning i forening med oral prævention DK1933843T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05022324A EP1787649B1 (de) 2005-10-13 2005-10-13 Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption
PCT/EP2006/009867 WO2007042296A1 (de) 2005-10-13 2006-10-12 Verwendung von estradiolvalerat oder estradiol in kombination mit dienogest zur oralen therapie der dysfunktionellen uterinen blutung in einheit mit einer oralen kontrazeption

Publications (1)

Publication Number Publication Date
DK1933843T3 true DK1933843T3 (da) 2011-04-18

Family

ID=35811580

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05022324T DK1787649T3 (da) 2005-10-13 2005-10-13 Anvendelse af estradiovalerat i kombination med dienogest til oral behandling af dysfunktionel uterin blöding i enhed med en oral kontraception
DK06806225.6T DK1933843T3 (da) 2005-10-13 2006-10-12 Anvendelse af østradiolvalerat eller østradiol kombineret med dienogest til oral terapi af dysfunktionel livmoderblødning i forening med oral prævention

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK05022324T DK1787649T3 (da) 2005-10-13 2005-10-13 Anvendelse af estradiovalerat i kombination med dienogest til oral behandling af dysfunktionel uterin blöding i enhed med en oral kontraception

Country Status (22)

Country Link
EP (2) EP1787649B1 (da)
JP (2) JP5735200B2 (da)
KR (2) KR20080065651A (da)
CN (1) CN101312733A (da)
AR (1) AR056694A1 (da)
AT (2) ATE424828T1 (da)
CA (1) CA2623024C (da)
CL (1) CL2011000283A1 (da)
CY (2) CY1110321T1 (da)
DE (2) DE502005006837D1 (da)
DK (2) DK1787649T3 (da)
DO (1) DOP2006000221A (da)
ES (2) ES2322479T3 (da)
HR (1) HRP20090256T1 (da)
ME (1) ME01056B (da)
PE (2) PE20100090A1 (da)
PL (2) PL1787649T3 (da)
PT (2) PT1787649E (da)
SI (2) SI1787649T1 (da)
TW (2) TWI328453B (da)
UY (1) UY29861A1 (da)
WO (1) WO2007042296A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
ES2322479T3 (es) * 2005-10-13 2009-06-22 Bayer Schering Pharma Aktiengesellschaft Utilizacion de valerato de estradiol en combinacion con dienogest para la terapia por via oral de la hemorragia uterina disfuncional, en union con una contracepcion oral.
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
AU4043597A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen
US6251956B1 (en) 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
EP1462106A1 (en) * 2003-03-28 2004-09-29 Pantarhei Bioscience B.V. Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
ES2322479T3 (es) * 2005-10-13 2009-06-22 Bayer Schering Pharma Aktiengesellschaft Utilizacion de valerato de estradiol en combinacion con dienogest para la terapia por via oral de la hemorragia uterina disfuncional, en union con una contracepcion oral.

Also Published As

Publication number Publication date
EP1933843A1 (de) 2008-06-25
EP1933843B1 (de) 2011-02-02
ATE497387T1 (de) 2011-02-15
KR20080065651A (ko) 2008-07-14
PT1787649E (pt) 2009-05-08
CY1110321T1 (el) 2015-01-14
SI1787649T1 (sl) 2009-08-31
CA2623024A1 (en) 2007-04-19
EP1787649B1 (de) 2009-03-11
WO2007042296A1 (de) 2007-04-19
CN101312733A (zh) 2008-11-26
AR056694A1 (es) 2007-10-17
EP1787649A1 (de) 2007-05-23
ES2360302T3 (es) 2011-06-02
JP2013047269A (ja) 2013-03-07
PE20100090A1 (es) 2010-03-12
JP2009511526A (ja) 2009-03-19
CY1111406T1 (el) 2015-08-05
CA2623024C (en) 2012-03-06
DOP2006000221A (es) 2007-08-31
JP5735200B2 (ja) 2015-06-17
CL2011000283A1 (es) 2011-07-08
KR20100082389A (ko) 2010-07-16
HRP20090256T1 (en) 2009-06-30
DK1787649T3 (da) 2009-06-02
ME01056B (me) 2012-10-20
PE20070555A1 (es) 2007-07-12
KR101218872B1 (ko) 2013-01-07
PL1787649T3 (pl) 2009-08-31
PL1933843T3 (pl) 2011-06-30
SI1933843T1 (sl) 2011-06-30
DE502005006837D1 (de) 2009-04-23
ATE424828T1 (de) 2009-03-15
TW200829255A (en) 2008-07-16
DE502006008853D1 (de) 2011-03-17
PT1933843E (pt) 2011-04-29
TWI328453B (en) 2010-08-11
ES2322479T3 (es) 2009-06-22
UY29861A1 (es) 2007-05-31
TW200731977A (en) 2007-09-01

Similar Documents

Publication Publication Date Title
BRPI0813000A2 (pt) Composições terapêuticas e uso das mesmas
DK1827412T3 (da) Sammensætninger til anvendelse i kirurgi
IL187982A0 (en) Human placental collagen compositions, processes for their preparation, methods of their use and kits comprising the compositions
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
ITCO20050028A1 (it) Complesso di acceleratori di protoni in particolare per uso medicale
WO2009054996A8 (en) Systems and methods for viral therapy
SG10201701904TA (en) Management of breakthrough bleeding in extended hormonal contraceptive regimens
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
IL212960A (en) Sulfonamide derivatives, the vehicle containing them and their use in cancer treatment
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
CL2007002377A1 (es) Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
BRPI0912292A2 (pt) composições e métodos para o uso de células no tratamento do tecido cardíaco.
CR10454A (es) Composiciones farmaceuticas novedosas de baja dosis que comprenden nimesulida , preparacion y uso de las mismas
NO20071297L (no) Farmasøytisk sammenseting omfattende drospirenon og etynylestradiol
DK2087890T3 (da) Præparat med vedvarende frigørelse til vævsregenereringsterapi
BRPI0911945A2 (pt) cc10 humana recombinante e suas composições para uso no tratamento de rinite nasal
BRPI0813736A2 (pt) Oxazolidinon-5-il-metil)-2-tiofeno-carboxamidas substituídas e uso das mesmas na área da coagulação do sangue
DK1933843T3 (da) Anvendelse af østradiolvalerat eller østradiol kombineret med dienogest til oral terapi af dysfunktionel livmoderblødning i forening med oral prævention
DK2188253T3 (da) Indol-2-onderivater, der er disubstitueret i 3-stillingen, fremstilling deraf og terapeutisk anvendelse deraf
BRPI0914064A2 (pt) composição veterinária, uso de composição veterinária e kit veterinário
BRPI0807724A2 (pt) Composição para uso na odontologia
BRPI0913297A2 (pt) composição, farmacêutica, uso de uma composição, e, kit terapêutico.
DOP2010000400A (es) 7-sulfanilmetil-,7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
UY31139A1 (es) Formas cristalinas de 3-(2r-tetrahidrofuril-metil)-2-tioxantina